What is IPIC? 

 

The International Post-operative Intravesical Chemotherapy Study - Multi-centre Qualitative analysis of guideline adherence of peri-operative intravesical chemotherapy in non-muscle invasive bladder cancer

Contact Details and registration:  ipic.yuro@gmail.com

 

• Lead investigator: Dr Tatenda Nzenza

• Overall Recruitment Officer (RO): Dr Simeon Ngweso

• East coast RO: Dr Catriona Duncan

• Public relations: Dr Todd Manning

• IT: Dr Shannon McGrath

 

 

Study Objectives

​

• To investigate rate of use of post-operative intravesical chemotherapy for non-muscle invasive bladder cancer (NIMBC)

• To assess guideline compliance rate, patterns of use and barriers to use of intravesical chemotherapy for NMIBC

 

Aim

​

• Multi-centre retrospective audit of post-operative chemotherapy use for NIMBC

• Across Australia, New Zealand, Canada and UK

• All patients who underwent TURBT for suspected NIMBC in 2016

• RedCaps Database

 

Inclusion Criteria

​

• Age >18 yrs

• TURBT

• As defined by operation note: Lesion suspected to be low grade at time of procedure (Ta/1), completely resected solitary papillary tumour

​

Exclusion Criteria

​

• Age <18 years

• High grade bladder cancer, CIS, multifocal (>1) or >3cm

• Currently receiving ongoing intravesical chemotherapy

 

 

 

Recruitment closes 1st March 2018 - Register NOW!